Ionis Q1 Revenue Soars 87%, Beats Estimates and Boosts Full-Year Guidance
Summary
Ionis Pharmaceuticals reported a strong first quarter, with revenue surging 87% year-over-year to $246 million, significantly exceeding analyst expectations of $195.63 million. This robust performance was primarily driven by higher product sales of TRYNGOLZA and DAWNZERA, as well as substantial R&D milestone payments totaling $95 million from partnerships. Following these results, the company raised its 2026 total revenue guidance to $875-900 million from the previous $800-825 million, and also increased annual olezarsen peak net sales guidance to over $3 billion for sHTG. While operating expenses rose due to commercialization investments, the strong revenue growth and improved outlook are highly positive for the stock, indicating strong execution and pipeline potential. Traders will monitor continued product sales growth and further pipeline advancements.
At the time of this announcement, IONS was trading at $71.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $29.42 to $86.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.